On the stock market since 1999, it operates in the world of health and science. It has 42 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
An average decline of 15% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
If every debt were paid off today, $8.1M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 1,254% — still a thick cushion, though costs have been eating into it lately.
There is $11.4M in the vault; even if every debt were paid off, $8.1M would remain.
The average analyst price target is $1.00 — 315% above today’s price.
The stock sits at $0.24. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 3 years, sales fell about 48% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, PTE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PTE is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.